SeekingAlpha · Oct 30, 2026
Gilead Sciences: Why I Remain Bullish After Q3
Gilead Sciences had a strong Q3, while successfully shifting its R&D focus from HIV to the immunology market. Read why GILD stock is a buy.
NASDAQ · GSK
GSK plc
Healthcare · Drug Manufacturers - General
$49.51
Up+$0.83 (+1.71%)
Updated Oct 31, 2026, 5:28 PM
SID Score
6.5/10
Composite research score
Smart Money
60/100
Neutral
- Market cap
- 99.39B
- P/E ratio
- 13.41
- Dividend yield
- 3.38%
- 52-week range
- $42.89 – $61.70
- Volume
- 4.77M
- Avg. volume
- 5.18M
Price performance · GSK
GSK price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
GSK closed at $49.51 after 21 trading sessions, up 5.27% for the selected period.
- Last close
- $49.51
- Period change
- +5.27%
- Period low
- $46.27
- Period high
- $51.21
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $49.84 | $50.28 | $49.25 | $49.51 | 4.77M |
| Oct 29, 2026 | $48.19 | $49.11 | $48.025 | $48.68 | 5.61M |
| Oct 28, 2026 | $47.65 | $49.32 | $47.355 | $48.74 | 8.12M |
| Oct 27, 2026 | $50.80 | $51.25 | $50.635 | $50.94 | 4.77M |
| Oct 26, 2026 | $50.86 | $51.235 | $50.85 | $51.10 | 3.61M |
| Oct 23, 2026 | $50.83 | $50.92 | $50.29 | $50.75 | 3.18M |
| Oct 22, 2026 | $50.29 | $51.435 | $49.965 | $51.21 | 4.28M |
| Oct 21, 2026 | $50.19 | $50.445 | $49.91 | $50.02 | 3.61M |
| Oct 20, 2026 | $49.98 | $51.1205 | $49.77 | $50.63 | 5.6M |
| Oct 19, 2026 | $49.435 | $49.81 | $49.26 | $49.46 | 5.37M |
| Oct 16, 2026 | $49.615 | $49.965 | $49.435 | $49.51 | 6.92M |
| Oct 15, 2026 | $49.18 | $49.84 | $48.975 | $49.02 | 6.14M |
| Oct 14, 2026 | $46.63 | $47.98 | $46.55 | $47.87 | 7.09M |
| Oct 13, 2026 | $47.09 | $47.15 | $46.105 | $46.27 | 5.76M |
| Oct 12, 2026 | $46.70 | $47.085 | $46.31 | $46.92 | 10.35M |
| Oct 9, 2026 | $46.61 | $46.82 | $46.265 | $46.50 | 8.54M |
| Oct 8, 2026 | $46.40 | $46.70 | $45.825 | $46.54 | 7.73M |
| Oct 7, 2026 | $46.92 | $47.405 | $46.69 | $47.02 | 5.85M |
| Oct 6, 2026 | $46.96 | $47.01 | $46.175 | $46.60 | 6.81M |
| Oct 5, 2026 | $46.73 | $46.885 | $46.33 | $46.55 | 3.48M |
| Oct 2, 2026 | $47.08 | $47.16 | $46.84 | $47.03 | 5.39M |
Latest GSK news
The latest Smart Investors Daily articles mentioning GSK.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GSK research
Overview
Company profile and research snapshot.
Company profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $53.00
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | Deutsche | Hold | — |
| May 28, 2026 | Jefferies | Buy | — |
| May 27, 2026 | Deutsche | Hold | — |
| May 6, 2026 | Deutsche | Hold | — |
| May 6, 2026 | Citigroup | Neutral | — |
News briefing
Generated Oct 31, 2026, 5:06 PM
Why Is GSK Up Today? Q3 Momentum Meets Analyst Skepticism
GSK shares gained 1.71% today as positive Q3 earnings momentum continued to resonate with investors, despite a notable downgrade from Jefferies that signals caution ahead. The stock is caught between accelerating operational improvements and growing concerns about sustainability of recent performance.
Bottom line: GSK's 1.71% gain reflects positive Q3 earnings momentum, but the recent Jefferies downgrade serves as a reality check on the stock's valuation and growth outlook. Investors should closely monitor whether management can navigate the identified 'bumps ahead' while competing against faster-growing biotech peers—the sustainability of recent gains remains questionable at current valuations.
SeekingAlpha · Oct 30, 2026
GSK: The Gas Pedal Is Still Down, But Bumps Ahead
GSK stock remains a Buy despite Q3 misses, with Specialty Medicines growth, pipeline momentum, valuation upside, and key risks to watch. See more here.
Benzinga · Oct 29, 2026
Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9
Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.
Yahoo · Oct 29, 2026
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
